Skip to Content

Join the 'Leukemia' group to help and get support from people like you.

Leukemia News

Related terms: Cancer, Leukemia

Could IVF Raise Children's Odds for Blood Cancer?

Posted 8 days ago by Drugs.com

THURSDAY, Feb. 4, 2016 – Children conceived through in vitro fertilization (IVF) might have a slightly increased risk of developing blood cancer, a new study suggests. Children born via IVF had a 67 percent increased risk of leukemia and a more than tripled risk of Hodgkin's lymphoma compared to children conceived naturally, researchers found in an analysis of more than 1.6 million children in Norway. Parents shouldn't panic, however. The risk of childhood cancer is still very small, even after factoring in the results of this study, said lead author Dr. Marte Myhre Reigstad. She is a researcher with the Norwegian National Advisory Unit on Women's Health at Oslo University Hospital. "For example, in Norway, the risk of being diagnosed with leukemia within the first 10 years of life is 0.5 in 1,000," Reigstad said. "A risk increase of such magnitude as found in our study would amount to ... Read more

Related support groups: Leukemia, Female Infertility, Lymphoma, Ovulation Induction, Primary Ovarian Failure, Follicle Stimulation

Genmab Announces U.S. FDA Approval of Arzerra (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL

Posted 20 Jan 2016 by Drugs.com

Copenhagen, Denmark; January 19, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the use of Arzerra (ofatumumab) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). The application was submitted by Novartis under the ofatumumab collaboration between the two companies. This FDA approval is based on data from an interim analysis from a Phase III study, PROLONG (OMB112517) which evaluated ofatumumab maintenance therapy versus no further treatment in patients with a complete or partial response after second or third line treatment for CLL. "The approval of Arzerra in the U.S. as extended treatment provides patients with relapsed CLL with a ... Read more

Related support groups: Leukemia, Chronic Lymphocytic Leukemia (CLL), Arzerra, Ofatumumab

Antibody May Lower Rejection Rates After Stem Cell Transplant in Leukemia Patients

Posted 7 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 6, 2016 – People with acute leukemia who were given antibody therapy before a stem cell transplant fared better than those who didn't receive the treatment, a small study found. Stem cell transplantation allows doctors to give higher doses of cancer-killing chemotherapy, according to the American Cancer Society. However, the odds of the body rejecting the transplanted stem cells are very high – a condition called graft-versus-host disease, the study authors explained. By treating patients first with animal-derived antibodies, called antihuman T-lymphocyte immune globulin (ATG), the researchers were able to lower the threat of rejection in patients. "Graft-versus-host disease is the most serious complication after stem cell transplantation," said lead researcher Dr. Francesca Bonifazi, from the Institute of Hematology at Bologna University in Italy. "Using [ATG] reduces ... Read more

Related support groups: Hairy Cell Leukemia, Chronic Myelogenous Leukemia (CML), Leukemia, Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Chronic Eosinophilic Leukemia, Acute Nonlymphocytic Leukemia, Acute Promyelocytic Leukemia, Infection Prophylaxis, Chronic Lymphocytic Leukemia, Acute Myeloblastic Leukemia, Meningeal Leukemia

End-of-Life Talk Often Comes Too Late for Blood Cancer Patients

Posted 21 Dec 2015 by Drugs.com

MONDAY, Dec. 21, 2015 – Many doctors wait too long to have end-of-life discussions with blood cancer patients, a new study finds. Researchers analyzed surveys completed by 349 blood cancer specialists, and found that 56 percent said end-of-life discussions with patients happen too late. Nearly 43 percent said they had their first end-of-life discussions with patients at less-than-ideal times, the findings showed. About 23 percent of the doctors said they waited until death was imminent before discussing hospice care. And nearly 40 percent waited until death was imminent before they asked patients where they wanted to die. Several factors may contribute to the delay in end-of-life discussions with blood cancer patients, according to Dr. Oreofe Odejide, from the Dana-Farber Cancer Institute in Boston, and colleagues. While solid tumors are incurable after they reach an advanced stage, ... Read more

Related support groups: Cancer, Hairy Cell Leukemia, Chronic Myelogenous Leukemia (CML), Leukemia, Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Nonlymphocytic Leukemia, Chronic Eosinophilic Leukemia, Infection Prophylaxis, Chronic Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Acute Myeloblastic Leukemia, Meningeal Leukemia

Researchers Focus on Risk Factors for Leukemia After Breast Cancer Treatment

Posted 7 Dec 2015 by Drugs.com

MONDAY, Dec. 7, 2015 – Researchers say they're zeroing in on factors that may increase the risk of leukemia after breast cancer treatment. The findings are a step forward in determining ways to prevent this complication in breast cancer survivors. While the breast cancer treatments target malignant cells, they can also affect healthy cells and could increase the risk of leukemia later, the researchers said. The scientists looked at 88 breast cancer survivors with treatment-related leukemia and found that many had a personal and family history of cancer, suggesting a genetic susceptibility to cancer. Also, 20 percent of the women had an inherited gene mutation that increases the risk of breast cancer, according to the study published Dec. 7 in the journal Cancer. "The findings justify a long-term, follow-up study of women with and without inherited breast cancer gene mutations who are ... Read more

Related support groups: Provera, Depo-Provera, Breast Cancer, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Leukemia, Femara, Lupron Depot, Zoladex, Breast Cancer, Metastatic, Anastrozole, Evista, Megace, Megestrol, Aromasin, Letrozole, Herceptin, Casodex

Childhood Cancer Tied to Raised Risk for Other Ills in Adult Life

Posted 11 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 11, 2015 – Childhood cancer survivors are at increased risk for diabetes and other autoimmune diseases, a new study suggests. "Cure is no longer a sufficient goal in childhood cancer care," the researchers wrote. "As the vast majority of these patients survive, attention must be paid to their long-term quality of life and health challenges." In the study, the investigators analyzed data from more than 20,000 adults in Denmark, Iceland and Sweden, who had cancer before the age of 20 and survived for at least one year, and compared them to nearly 126,000 adults who did not have childhood cancer. Over an average follow-up of 15 to 19 years, 3.6 percent of childhood cancer survivors were treated in a hospital at least once for an autoimmune disease. That rate is 40 percent higher than among the adults who did not have childhood cancer, according to Dr. Anna Sallfors ... Read more

Related support groups: Diabetes, Type 2, Cancer, Leukemia, Autoimmune Disorders, Brain Tumor, Hodgkin's Lymphoma

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is a patient demographic that has been largely overlooked," said senior study author Dr. Robert Goldsby, a professor of pediatrics at the University of California, San Francisco Benioff Children's Hospital. Over 30 years, nearly 14 percent of the survivors were diagnosed with another, different type of cancer. On average, the second cancer occurred within 15 years. Compared to people in the general population, patients successfully treated for cancer between ages 15 and 39 were nearly 60 percent ... Read more

Related support groups: Cancer, Breast Cancer, Hairy Cell Leukemia, Chronic Myelogenous Leukemia (CML), Leukemia, Lymphoma, Basal Cell Carcinoma, Melanoma, Skin Cancer, Chronic Lymphocytic Leukemia (CLL), Ovarian Cancer, Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Stomach Cancer, Cutaneous T-cell Lymphoma, Acute Lymphoblastic Leukemia, Hodgkin's Lymphoma, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia, Testicular Cancer

Breast-feeding May Lower Risk of Childhood Leukemia: Study

Posted 1 Jun 2015 by Drugs.com

MONDAY, June 1, 2015 – Breast-feeding – even for a short time – may lower a baby's later risk of childhood leukemia, a new study suggests. The researchers found that babies breast-fed for at least six months appear to have a 19 percent lower risk of childhood leukemia compared to children who were never breast-fed or were breast-fed for fewer months. "Breast-feeding is a highly accessible and low-cost preventive public health measure that has been found in numerous studies to be associated not only with lower risk for childhood leukemia but also with lower risk for Sudden Infant Death Syndrome (SIDS), gastrointestinal infection, ear infection, type 2 diabetes and obesity later in life," said the study's lead author, Efrat Amitay, of the School of Public Health at the University of Haifa in Israel. "There is, therefore, a distinct public benefit in breast-feeding and it should be ... Read more

Related support groups: Leukemia, Delivery, Labor Induction, Premature Labor, Lactation Suppression, Cesarean Section, Labor and Delivery including Augmentation

Kids Born to Older Dads May Face Risk of Blood Cancers

Posted 12 May 2015 by Drugs.com

TUESDAY, May 12, 2015 – Adults who were born to older fathers may be at increased risk for blood and immune system cancers such as leukemia and lymphoma, a new study suggests. This association is particularly strong among only children, the American Cancer Society investigators added. However, the study did not prove there was a cause-and-effect link between the two. There was no association between having an older mother and increased risk of these cancers, according to the study published online May 11 in the American Journal of Epidemiology. "The lifetime risk of these cancers is fairly low – about one in 20 men and women will be diagnosed with lymphoma, leukemia or myeloma at some point during their lifetime – so people born to older fathers should not be alarmed," study leader Lauren Teras said in a journal news release. "Still, the study does highlight the need for more ... Read more

Related support groups: Leukemia, Lymphoma, Multiple Myeloma

Contagious Leukemia Killing East Coast Clams

Posted 9 Apr 2015 by Drugs.com

THURSDAY, April 9, 2015 – A lethal marine cancer killing clams along North America's East Coast is contagious, new research indicates. Scientists say they've traced leukemia outbreaks among soft-shell clams from New York to Canada back to one case of cancer, which was transmitted to other clams. "The evidence indicates that the tumor cells themselves are contagious – that the cells can spread from one animal to another in the ocean," said researcher Stephen Goff of the Howard Hughes Medical Institute and Columbia University in New York City. "We know this must be true because the genotypes of the tumor cells do not match those of the host animals that acquire the disease, but instead all derive from a single lineage of tumor cells," Goff explained. The findings, published April 9 in Cell, suggest that cells can survive in seawater long enough to reach and infect a new host. The ... Read more

Related support groups: Leukemia

Gene Mutations Tied to Leukemia Rise With Age, Study Finds

Posted 26 Feb 2015 by Drugs.com

THURSDAY, Feb. 26, 2015 – For many people, an increase in genetic mutations that could trigger leukemia seems to be an inevitable part of aging, a new study finds. The British researchers looked specifically at mutations in blood stem cells. "Over time, the probability of these cells acquiring mutations rises," co-lead author Thomas McKerrell, of the Wellcome Trust Sanger Institute, said in an institute news release. "What surprised us was that we found these mutations in such a large proportion of elderly people," he added. In the study, researchers looked at more than 4,200 people without any evidence of blood cancer. They found that up to 20 percent of people aged 50 to 60, and more than 70 percent of people older than 90, have blood cells with the same gene changes seen in leukemia. Just carrying a particular mutation doesn't mean that a leukemia is guaranteed, however. "Leukemia ... Read more

Related support groups: Blood Disorders, Leukemia

Breast Cancer Chemo Tied to Small But Significant Leukemia Risk

Posted 5 Jan 2015 by Drugs.com

WEDNESDAY, Dec. 24, 2014 – Among early stage breast cancer patients who undergo chemotherapy and/or radiation treatment, less than half of one percent will eventually develop leukemia as a result of their treatment, a new analysis reveals. The finding comes from a review of more than 20,000 breast cancer cases treated between 1998 and 2007, and it suggests that the risk for developing treatment-related leukemia, though low, is still double what experts had previously thought. "The frequency of bone marrow cancers such as leukemia is small, there's no question about it," study lead author Dr. Judith Karp, professor emerita of oncology at the Johns Hopkins University School of Medicine in Baltimore, noted in a university news release. "However, the cumulative risk over a decade is now shown to be twice as high as we thought it was, and that risk doesn't seem to slow down five years after ... Read more

Related support groups: Breast Cancer, Leukemia

Screening Test Approved for Viruses That Cause Blood Cancer

Posted 11 Dec 2014 by Drugs.com

THURSDAY, Dec. 11, 2014 – A new screening test to detect Human T-Cell Lymphotropic viruses that cause a rare blood cancer has been approved by the U.S. Food and Drug Administration. The viruses, abbreviated HTLV-I/II, cause diseases such as adult T-cell leukemia/lymphoma (blood cancer) and myelopathy (inflammation of spinal cord nerves) , the FDA said in a news release. HTLV can be transmitted via breastfeeding, unprotected sex or blood transfusion. The newly approved test – MP Diagnostics HTLV Blot 2.4 – is meant to supplement existing screening for the viruses, the FDA said. The diagnostic also can differentiate between the two types, HTLV-I or HTLV-II. Many people infected with HTLV may not be aware of its presence, since the virus does not always trigger symptoms. An infected person can transmit the virus without showing any signs or symptoms, the agency said. The new test is ... Read more

Related support groups: Leukemia, Lymphoma, Diagnosis and Investigation

FDA Approves Blincyto (blinatumomab) for Precursor B-Cell Acute Lymphoblastic Leukemia

Posted 3 Dec 2014 by Drugs.com

December 3, 2014 – The U.S. Food and Drug Administration today approved Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL. Precursor B-cell ALL is a rapidly growing type of cancer in which the bone marrow makes too many B-cell lymphoblasts, an immature type of white blood cell. The Philadelphia chromosome is an abnormality that sometimes occurs in the bone marrow cells of leukemia patients. The National Cancer Institute estimates that 6,020 Americans will be diagnosed with ALL and 1,440 will die from the disease in 2014. Blincyto is an example of immunotherapy, a treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. Blincyto is the first approved drug that engages the body’s T-cells, a type of white blood cell or lymphocyte, to des ... Read more

Related support groups: Leukemia, Acute Lymphoblastic Leukemia

Mutations Linked to Blood Cancers Rise With Age, Study Shows

Posted 22 Oct 2014 by Drugs.com

WEDNESDAY, Oct. 22, 2014 – Blood cell mutations linked to the blood cancers leukemia and lymphoma increase as people get older, according to a new study. Researchers analyzed blood samples from nearly 3,000 Americans, ages 10 to 90, and found the mutations in less than 1 percent of those ages 40 to 49. By the time people are between 70 and 79, 5 percent will have blood cell mutations, according to the study. For people between 80 and 89, more than 6 percent will be affected, the researchers found. Cell mutations accumulate as people age, and most are harmless, according to the researchers. They said that having these blood cell mutations associated with leukemia and lymphoma doesn't mean a person will develop these blood cancers. In fact, the diseases occur in less than 0.1 percent of elderly Americans, the researchers noted. "But it's quite striking how many people over age 70 have ... Read more

Related support groups: Leukemia, Lymphoma

Page 1 2 3 4 Next

Ask a Question

Further Information

Related Condition Support Groups

Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Nonlymphocytic Leukemia, Hairy Cell Leukemia, Acute Myeloblastic Leukemia, Chronic Eosinophilic Leukemia, Meningeal Leukemia, Blood Disorders

Related Drug Support Groups

prednisone, dexamethasone, triamcinolone, Decadron, Sprycel, Kenalog-40, dasatinib, Deltasone, cytarabine, view more... Liquid Pred, Sterapred DS, Dexone, Adrenocot LA, Adrenocot, Cytosar, Cytosar-U, Fludara, Sterapred, fludarabine, Dexpak Taperpak, Prednicot, Prednicen-M, Orasone, Clinacort, Dalalone LA, Decaject, Decaject LA, Zema Pak, Dalalone DP, Dalalone, Dexamethasone Intensol, Oforta, Baycadron, Idamycin, Dexasone LA, Decadron-LA, Solurex LA, Dexacen-4, Hexadrol, Tarabine PFS, idarubicin, Idamycin PFS, Solurex, De-Sone LA, Dexacorten, Medidex, Medidex LA, Primethasone, Dexone LA, Dexacort-LA, Dexasone, Meticorten